Top-Line Results from Pivotal Study of CereKin in Dogs with Osteoarthritis Conference Call

/in , , /by

Wednesday, August 20, 2014
Time of call: 5:30pm ET/ 2:30pm PST

Participant Toll-free Dial-in number: (855) 433-0927
Participant International Dial-in number: (484) 756-4262
Conference ID: 91627369

Kindred Biosciences Announces Top-Line Results from Pivotal Study of CereKin in Dogs with Osteoarthritis

/in , , /by

SAN FRANCISCO, California. (Aug 20, 2014) – Kindred Biosciences, Inc. (KindredBio, NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, announced today that its pivotal field study (KB010) of CereKin, an interleukin-1 inhibitor for the control of pain and inflammation associated with osteoarthritis in dogs, did not meet its primary endpoint. The randomized, double-blind, placebo-controlled study evaluated the safety and efficacy of two doses of CereKin (5 mg/kg and 20 mg/kg).

Read more

Kindred Biosciences Announces Second Quarter 2014 Financial Results

/in , , /by

San Francisco, CA (August 13, 2014) Kindred Biosciences, Inc. (NASDAQ: KIN) today announced financial results for the quarter ended June 30, 2014.

Conference Call and Webcast at 4:30 p.m. Eastern / 1.30 p.m. Pacific

“It is an exciting time for KindredBio as we develop our broad portfolio of drug candidates,” stated Richard Chin, M.D., President and Chief Executive Officer of KindredBio. “We currently anticipate the topline results from our pivotal study of CereKin shortly. The fact that we completed the entire study from start to finish in only 12 months, and on budget, is a testament to the quality and dedication of our team. As an organization, we continue to make top-notch science, patient benefit, and execution our top priorities.”

Read more

KindredBio Schedules Release of 2014 Second Quarter Financial Results and Provides Timeline for Release of CereKin Pivotal Study Data

/in , , /by

SAN FRANCISCO, California. (Aug 6, 2014) – Kindred Biosciences, Inc. (KindredBio, NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, announced the date for release of its 2014 second quarter financial results and provided the timeline for the release of topline data from its multi-center, pivotal clinical trial of CereKin™ for the treatment of osteoarthritis in dogs. The Company will release its 2014 second quarter financial results on August 13, 2014 after market close. The Company is on track to lock the database for the CereKin pivotal study in the first half of August and anticipates reporting the topline study data results during the week of August 18, 2014.

Read more